Eptinezumab-jjmr tightly binds and stays bound to CGRP, designed for sustained suppression of the CGRP signaling pathway1

Specifically designed with high selectivity and affinity for the CGRP ligand1

  • Binds to both α- and β-forms of the CGRP ligand1
  • No known off-target activity1
  • Strong binding with minimal dissociation (Kd = 4 pM)1
  • Relationship between pharmacodynamic activity and mechanism(s) by which eptinezumab-jjmr exerts its clinical effects is unknown2
  • The interaction and contact of CGRP to all 6 CDRs of eptinezumab-jjmr is consistent with the properties of specificity, durability, and strength of binding3

CDR, complementarity-determining region; CGRP, calcitonin gene-related peptide; Kd, dissociation constant; pM, picomolar.

Video of VYEPTI mechanism of action

Eptinezumab-jjmr IV is the only anti-CGRP that is 100% bioavailable—reaching Cmax in 30 minutes (at end of infusion).4

VYEPTI is designed for fast, powerful, and sustained response1,4

Immediate availability post-infusion4

VYEPTI IV infusion treatment icon

100% bioavailability post-IV administration4

Down arrow icon

Designed for rapid onset of activity4

Selective binding1

The only 100% bioavailable anti-CGRP

High selectivity for CGRP ligand1

Down arrow icon

Designed for no off-target activity1

Strong binding1

VYEPTI reaches Cmax at the end of infusion

High affinity for CGRP ligand1

Down arrow icon

Designed for sustained duration of action1

Eptinezumab-jjmr features were designed for rapid onset and sustained duration of action.1,4

Relationship between pharmacodynamic activity and the mechanism(s) by which eptinezumab-jjmr exerts its clinical effects is unknown.2

VYEPTI clinical trial data

Chronic and episodic migraine

VYEPTI IV treatment was evaluated for prevention of migraine in two phase 3 pivotal trials.2 See the changes from baseline in mean MMD (Months 1-3), Day 1 to Day 7, and more.

Dosing and administration

One 30-minute IV infusion every 3 months2

VYEPTI is the only anti-CGRP given as an IV treatment.2 See the administration details, including supplies, storage, and available doses.   

MMD, monthly migraine days.

You may also be interested in:

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

References:
  1. Garcia-Martinez LF, Raport CJ, Ojala EW, et al. Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide. J Pharmacol Exp Ther. 2020;374(1):93-103.
  2. VYEPTI (eptinezumab-jjmr) [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.
  3. Misura K, Scalley-Kim M, Olland A, White A, Latham J. The eptinezumab: CGRP complex structure and characterization of the ligand binding interface. Poster presented at: 61st Annual Scientific Meeting of the American Headache Society (AHS); July 11-14, 2019; Philadelphia, PA. P220LB.
  4. Baker B, Schaeffler B, Beliveau M, et al. Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Perspect. 8(2):e00567.